English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background : Radiaon absorbed dose to the red bone marrow, a crical organ in the therapy of thyroid carcinoma, is generally kept below 2 Gy for non-myeloablave therapies. The aim of this study was to calculate bone marrow radiaon dose by using MIRDOSE3 package program and to opmize the safe limit of acvity to be administered to the thyroid cancer paents. Materials and Methods : In this study, 83 thyroid cancer paents were divided into 3 groups based on the amount of acvity administered into the body. In the groups, 3700 MBq, 5550 MBq and 7400 MBq acvies were used respecvely. The curves ofme-acvity were drawn f rom blood samples counts and effecve half-life and residenceme were calculated. Correlaons of bone marrow radiaon dose and radioiodine effecv e half-life were determined as a funcon of administered acvity via ANOVA test. Tg levels and tumour diameters were compared using Spearman's correlaon. Results: The effecve half-lives of 131

Bone marrow radiation dosimetry of high dose 131I treatment in differentiated thyroid carcinoma patients